| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/29/2009 | US20090028813 Methods for Treating Body Tissue |
| 01/29/2009 | US20090028795 NOD1 as an Anti-Tumor Agent |
| 01/29/2009 | US20090028794 Uses and compositions for treatment of psoriatic arthritis |
| 01/29/2009 | US20090028788 Compounds having rd targeting motifs |
| 01/29/2009 | US20090026123 System for the production of autologus platelet gel useful for the delivery of medicinal and genetic agents |
| 01/29/2009 | DE102007037056A1 Hemostyptic made of freeze-dried collagen, useful e.g. to increase absorption capacity of liquids, preferably blood and treat blood vessel leakage, comprises a water-soluble biocompatible organic acid, preferably hydroxyl carboxylic acid |
| 01/29/2009 | DE102007037053A1 Hämostyptikum für die minimal-invasive Operation Hemostyptic for minimally invasive surgery |
| 01/29/2009 | DE102007033359A1 Verwendung eines Granulins oder einer Granulin-ähnlichen Verbindung zur Therapie oder Prophylaxe von chronischen Schmerzen Use of a granulin or granulin-like compound for the treatment or prophylaxis of chronic pain |
| 01/29/2009 | CA2722754A1 Modified plasminogen activator inhibitor type-1 molecule and methods based thereon |
| 01/29/2009 | CA2720628A1 Fusion proteins |
| 01/29/2009 | CA2697159A1 Antibodies to cd200 and uses thereof in inhibiting immune responses |
| 01/29/2009 | CA2694590A1 Modified lecithin-cholesterol acyltransferase enzymes |
| 01/29/2009 | CA2694440A1 Controlled release interferon drug products and treatment of hcv infection using same |
| 01/29/2009 | CA2694235A1 Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| 01/29/2009 | CA2694222A1 Insulin secretion inducer, and accelerator for increasing the number of pancreatic .beta.-cells |
| 01/29/2009 | CA2694214A1 Peptides derived from plasminogen activator inhibitor-1 and uses thereof |
| 01/29/2009 | CA2694205A1 Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof |
| 01/29/2009 | CA2694047A1 Use of mutated antithrombins for treating or preventing coagulation disorders |
| 01/29/2009 | CA2694046A1 Antimicrobial peptide, compositions, and methods of use |
| 01/29/2009 | CA2693996A1 Treating or ameliorating neuroinflammatory or demyelinating disorders with prolactin and an immunomodulator |
| 01/29/2009 | CA2693921A1 Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| 01/29/2009 | CA2693303A1 Natriuretic polypeptides |
| 01/29/2009 | CA2693277A1 Immune modulation via c-type lectin |
| 01/28/2009 | EP2019133A1 MICROORGANISM CAPABLE OF PRODUCING gamma-L-PGA, METHOD FOR PRODUCTION OF gamma-L-PGA USING THE MICROORGANISM, CROSSLINKED PRODUCT, AND AGENT FOR EXTERNAL APPLICATION TO THE SKIN |
| 01/28/2009 | EP2019118A1 Method for synthesizing thymosins |
| 01/28/2009 | EP2018871A1 Immunological methods to modulate myostatin in vertebrate subjects |
| 01/28/2009 | EP2018865A2 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate |
| 01/28/2009 | EP2018858A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic trioxide |
| 01/28/2009 | EP2018857A1 Medical device and use of a pharmaceutical composition |
| 01/28/2009 | EP2018185A1 Use of mas-g-protein-coupled receptor agonists in the treatment of the metabolic syndrome, its components and its complications |
| 01/28/2009 | EP2018180A2 Use of thymosin alpha 1 for the treatment of immunological diseases |
| 01/28/2009 | EP2018179A1 Use of antagonists of cxcl13 or cxcr5 for treating wounds or fibrotic diseases |
| 01/28/2009 | EP2018178A2 Administration of agonist-antagonist in opioid-dependent patients |
| 01/28/2009 | EP1906987A4 Methods and compositions for emergency contraception using endothelin receptor antagonists |
| 01/28/2009 | EP1725580B1 Isosteric transformation |
| 01/28/2009 | EP1470826B1 Decoy-containing pharmaceutical compositions for the treatment of aneurysms |
| 01/28/2009 | EP1372716B1 Blood cell production via activation of cd163 |
| 01/28/2009 | EP1207755B1 Use of a ribonuclease of the T2 family having actin-binding activity for inhibiting and/or reversing proliferation |
| 01/28/2009 | EP1073416B1 Use of inhaled no as anti-inflammatory agent |
| 01/28/2009 | CN101356269A Methods for expression and purification of recombinant human growth hormone |
| 01/28/2009 | CN101356193A Inhibition of the anti-FVIII immune response |
| 01/28/2009 | CN101356192A Compositions and methods for modulating hemostasis |
| 01/28/2009 | CN101356189A Hepatocyte growth factor intron fusion proteins |
| 01/28/2009 | CN101356186A Prion-specific peptoid reagents |
| 01/28/2009 | CN101355959A Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| 01/28/2009 | CN101355958A Interferon-alpha and c-phycocyanin for the treatment of autoimmune diseases, allergic diseases and cancer |
| 01/28/2009 | CN101355957A Methods for fusion polypeptide delivery into a cell |
| 01/28/2009 | CN101355956A Use of complement pathway inhibitors to treat ocular diseases |
| 01/28/2009 | CN101355955A Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
| 01/28/2009 | CN101355928A Compositions and methods for cancer immunotherapy |
| 01/28/2009 | CN101353688A Preparation and use of kudzu root peptides |
| 01/28/2009 | CN101353687A Melissa powder peptides having angiotensin transferase inhibitory activity and preparation thereof |
| 01/28/2009 | CN101353668A Mouse beta-alexin 1 recombinant plasmids, polypeptides, uses and preparations thereof |
| 01/28/2009 | CN101353663A Anti-I type diabetes fuse protein and preparation thereof |
| 01/28/2009 | CN101353381A Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| 01/28/2009 | CN101353380A Jellyfish origin immune activity enhanced collagen peptide, preparation and use thereof |
| 01/28/2009 | CN101353378A Zone 2 protein of programmed cell death protein 2 analogue and uses thereof |
| 01/28/2009 | CN101353377A Zone 1 protein of programmed cell death protein 2 analogue and uses thereof |
| 01/28/2009 | CN101352573A Recombinant human granulocyte colony stimulating factor lysine defect body modified by polyethyleneglycol |
| 01/28/2009 | CN101352568A New use of specific sodium channel modulation preparation BmK IT2 |
| 01/28/2009 | CN101352365A Positioner for fixing micro organs |
| 01/28/2009 | CN101352234A Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 01/28/2009 | CN100455595C Protein of interreaction with karyomitosis primary activator protein kinase p38 and its coding gene and application |
| 01/28/2009 | CN100455594C Polypeptide of controlling IIIv virus fusion and its use |
| 01/28/2009 | CN100455324C Externally applied liquid prepn of recombinant human granulocyte-macrophage colony stimulating factor |
| 01/27/2009 | US7482448 Compounds and compositions as cathepsin inhibitors |
| 01/27/2009 | US7482442 HEMCM42 nucleic acids |
| 01/27/2009 | US7482440 Hemopoietin receptor protein, NR10 |
| 01/27/2009 | US7482433 Peptides of sequence of amino acids where one or more of the peptidyl [ C(O)NR ] linkages (bonds) have been replaced by a non-peptidyl linkage; IL-5 antagonists treating asthma |
| 01/27/2009 | US7482429 cyclic depsipeptides and/or mimetics, used as anticarcinogenic agents, formed by cyclization of polypeptides |
| 01/27/2009 | US7482428 Optimized expression of HPV 31 L1 in yeast |
| 01/27/2009 | US7482427 Synthetic peptides having a non growth factor heparin binding region, a linker, and sequences; treatment of bone lesions, degenerative joint disease and to enhance bone formation |
| 01/27/2009 | US7482426 C23 Polypeptides |
| 01/27/2009 | US7482425 Compositions for lipid matrix-assisted chemical ligation |
| 01/27/2009 | US7482379 protease inhibitors more specifically to peptide inhibitors of cysteine proteases; viral infections, stroke, neurodegenerative disease, inflammatory diseases,autoimmune diseases like lupus, cancer; alpha aza-amino acid residues; prevent proteolysis |
| 01/27/2009 | US7482332 For therapy of macular degeneration, the effects of skin aging, liver degeneration, and cancer |
| 01/27/2009 | US7482331 Treating myocardial failure in a human by administering an effective amount of a transgene encoding for alpha-MHC, wherein expression of alpha-MHC provides improvement in left ventricular ejection fraction |
| 01/27/2009 | US7482329 Structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like (tissue differentiation factor) receptors; methods of detecting, preventing, and treating TDF-associated disorders |
| 01/27/2009 | US7482328 an artificially synthesized antimicrobial polypeptide that does not occur in nature contains in its peptide chain one or more types of nuclear localization signal sequences (NLSs); for drug resistance bacteria |
| 01/27/2009 | US7482327 administering to a patient an effective dose of a CTLA4 mutant molecule containing an extracellular domain of CTLA4 beginning with alanine at position 26 or methionine at position 27 and ending with aspartic acid at position 150; immunosuppressive therapies to block T-cell activation and function; kidney |
| 01/27/2009 | US7482326 endothelial-monocyte activating polypeptide III (EMAP III) cDNA encoding such proteins; anticarcinogenic agent; diagnostically or therapeutically useful |
| 01/27/2009 | US7482325 Downregulation of immune response by administering B7RP-2 fusion protein |
| 01/27/2009 | US7482324 Bone morphogenic protein for identifying modulators for treatment of bone diseases |
| 01/27/2009 | US7482323 Intracellular interleukin-1 receptor antagonist and uses thereof |
| 01/27/2009 | US7482322 Plexin family-like polypeptide, and uses thereof |
| 01/27/2009 | US7482321 Extended glucagon-like peptide-1 analogs |
| 01/27/2009 | US7482320 Modulation of smooth muscle cell proliferation |
| 01/27/2009 | US7482319 delivery of enzyme, a pharmaceutical agent, a plasmid, a polynucleotide, a polypeptide, a sensor to an organism, tissue or cell by incorporting into a vault like particle such as polypeptide, linked to MVP, VPARP, a portion of VPARP, or a modified MVP, VPARP; adminstering |
| 01/27/2009 | US7482318 Administering polynucleotides, BCL genes or proteins, fusion proteins and/or carrier mixtures, as antiapoptotic agents |
| 01/27/2009 | US7482171 Angiotensin converting enzyme homolog and uses therefor |
| 01/27/2009 | US7482159 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds |
| 01/27/2009 | US7482149 Inhibition of SARS coronavirus infection with clinically approved antiviral drugs |
| 01/27/2009 | US7482147 polypeptides, proteins or fusion proteins having hydrolase enzyme activity, used for medical diagnosis and therapy |
| 01/27/2009 | US7482138 PAK5-related compositions and methods |
| 01/27/2009 | US7482130 Screening compounds which modulate ubiquitin ligase activity; cell proliferation; nuclear zinc finger protein (NP95); RNA interference; high throughput assay |
| 01/27/2009 | US7482126 Transcription factor as repressor of expression of E-cadherin; drug screening |
| 01/27/2009 | US7482024 highly dispersible mixture of drugs and dipeptides or tripeptides, in the form of liquids, aerosols or powders, administered by inhalation |
| 01/27/2009 | US7482014 Administering polyoxyethylene glycol modified interferon-alpha; immunotherapy |
| 01/27/2009 | US7482013 Albumin fusion proteins |
| 01/27/2009 | US7482012 Streptococcus pyogenes polypeptides and corresponding DNA fragments |